Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca. It is an endothelin receptor antagonist.
Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca. It is an endothelin receptor antagonist.
Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).